Mycobacterium tuberculosis

Overview

Mycobacterium tuberculosis is the bacterial pathogen responsible for tuberculosis (TB), a major global infectious disease that primarily affects the lungs but can also disseminate to other organs. It is an intracellular, slow-growing mycobacterium with a distinctive cell envelope and a strong capacity to persist within host macrophages, which contributes to chronic infection, immune evasion, and prolonged treatment requirements. In biomedical research, M. tuberculosis is commonly abbreviated as Mtb or MTB.

The organism is a central target in anti-tubercular drug discovery, vaccine development, host-directed therapy, and diagnostic research. Its biology is studied through virulence factors, metabolic pathways, and strain-specific differences, including drug-sensitive and drug-resistant isolates. Recent work has also focused on antigenic targets such as Ag85B and PstS1, essential enzymes and pathways such as InhA and biotin biosynthesis, and host-pathogen interactions involving macrophage survival, ferroptosis, and inflammatory signaling.

Focus of Latest Publications

Recent publications on Mycobacterium tuberculosis have focused on both direct antibacterial strategies and host-directed approaches. Several studies explored small-molecule inhibitors with activity against M. tuberculosis, including guanilated quinolones designed as dual Janus Kinase 3 inhibitors and antitubercular agents, with one compound showing potent JAK3 inhibition and antitubercular activity in the low micromolar range. Another medicinal chemistry study optimized piperazine-based BioA inhibitors targeting biotin biosynthesis, reporting that the lead compound C48 retained strong activity against drug-sensitive and drug-resistant M. tuberculosis strains and was validated for on-target engagement using isogenic strains with altered BioA expression.

Drug delivery and intracellular targeting were also prominent themes. An aptamer-based approach used monoolein cationic cubosome lipid nanoparticles to deliver the MS10-Trunc single-stranded DNA aptamer against M. tuberculosis malate synthase, improving antibacterial efficacy relative to the free aptamer and reducing the minimum inhibitory concentration against actively replicating MTB-H37Ra. In a separate therapeutic platform, a lesion-pathogen dual-targeting nanoparticle carrying anti-Ag85B antibody was developed for imaging-guided photothermal therapy; this system bound Ag85B of M. tuberculosis, generated localized hyperthermia, and showed strong antibacterial effects in a surrogate granuloma model, including marked reduction of bacterial burden in vitro and suppression of granuloma progression in vivo.

Host-pathogen interactions were addressed in work on pyrvinium pamoate, an FDA-approved anthelminthic drug. The study found that low-dose pyrvinium pamoate inhibited intracellular M. tuberculosis H37Rv/H37Ra survival in infected macrophages by suppressing ferroptosis, with mechanistic evidence implicating binding to CK1α and downstream effects on ATF4-xCT-GSH-GPX4 and YAP1-ACSL4/TFRC-Fe3+ pathways. This host-directed mechanism was reversed by CK1α knockdown or inhibition, supporting a role for ferroptosis modulation in limiting intracellular mycobacterial survival.

Other recent studies addressed resistance prediction and vaccine development. A machine learning analysis of whole-genome sequencing data from clinical isolates predicted bedaquiline resistance with good accuracy and identified features mapped to the H37Rv genome, including mutations associated with resistance and several newly implicated antibiotic-resistant genes. On the preventive side, rational deletion of virulence-related genes in M. tuberculosis was used to construct triple and quadruple knockout vaccine candidates; these strains showed enhanced immunogenicity relative to the double knockout parent, while the quadruple knockout strain was highly attenuated in SCID mice, suggesting potential for safer live-attenuated TB vaccines.

Key Publications

May Guanilated Quinolones with Dual Antitubercular and Anti-Inflammatory Activities. (ChemMedChem, 2026, PMID 42202039): "we investigated novel guanilated quinolones as dual inhibitors of Janus Kinase 3 (host target) and Mycobacterium tuberculosis."
Jun Precise Photothermal/Fluorescence Imaging-Guided Dual-Targeted Photothermal Therapy for Tuberculosis. (ACS applied bio materials, 2026, PMID 42133291): "the anti-Ag85B (marked as Tar in ICG-PEG-Tar NPs) precisely targets antigen 85B of Mycobacterium tuberculosis."
May Aptamer-Loaded Cubosome Lipid Nanoparticles for the Treatment of Tuberculosis. (ACS applied materials & interfaces, 2026, PMID 42117503): "A single stranded DNA (SSDA) aptamer was recently designed as an inhibitor for Malate Synthase (MS) of Mycobacterium tuberculosis (MTB)."
May Machine learning method for the prediction of Bedaquiline-resistant Mycobacterium tuberculosis. (Life science alliance, 2026, PMID 42061986): "The study addresses the increasing resistance to the FDA-approved drug Bedaquiline (BDQ) in Mycobacterium tuberculosis (MTB)."
May Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis. (Journal of medicinal chemistry, 2026, PMID 42017700): "targeting biotin biosynthesis in Mycobacterium tuberculosis (Mtb)."
May Construction and characterization of novel Mycobacterium tuberculosis-derived triple and quadruple knockout vaccines against tuberculosis. (Infection and immunity, 2026, PMID 42012295): "We have developed a strategy for the rational deletion of virulence-related genes in Mycobacterium tuberculosis (Mtb) to create hyperattenuation that also enhances immunogenicity."
Mar Pyrvinium pamoate inhibits the survival of intracellular Mycobacterium tuberculosis through suppression of macrophage ferroptosis. (Bioorganic chemistry, 2026, PMID 41875752): "Recently we have reported that pyrvinium pamoate can decrease mycobacterial burdens in Mycobacterium tuberculosis (M. tuberculosis)-infected macrophages and mice."